연구성과로 돌아가기
2024 연구자 정보 (49 / 1079)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Lee, Soo Jung (Lee, SJ) |
Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Hematol & Oncol, Daegu, South Korea Kyungpook Natl Univ, Sch Med, Dept Oncol Hematol, Daegu, South Korea Kyungpook Natl Univ, Dept Oncol Hematol, Chillgok Hosp, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Oncol Hematol,Canc Res Inst, Daegu, South Korea Kyungpook Natl Univ Hosp, Daegu, South Korea Kyungpook Natl Univ, Sch Med, Dept Oncol, Daegu, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ, Sch Med, Dept Oncol Hematol,Chilgok Hosp, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Hoguk Ro 807, Daegu 41404, South Korea |
A-5417-2013 Lee, Joong |
|
[JCR상위 1.7] Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer [JCR상위 36.0] Feasibility of an indocyanine green-hyaluronic acid mixture (LuminoMark™) for targeting suspicious axillary lymph nodes in patients with breast cancer [JCR상위 57.2] Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer [JCR상위 1.7] Uncovering of NRAGE/JNK and PI3K/AKT pathways through serial WGS of patients with breast cancer [JCR상위 70.5] Preoperative and Postoperative Platelet-Lymphocyte Ratio Is a Prognostic Marker for Patients With Soft Tissue Sarcoma Treated With Curative Resection [JCR상위 1.7] Preoperative and postoperative platelet-lymphocyte ratio as a prognostic marker for patients with soft tissue sarcoma treated with curative resection [JCR상위 11.5] Effectiveness of Carboplatin-Prescreening Intradermal Skin Tests to Reduce Unanticipated Immediate Hypersensitivity Reactions: A Comparative Study [JCR상위 44.0] Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer [JCR상위 65.0] Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer [JCR상위 1.7] Enhanced dacarbazine efficacy in advanced melanoma patients previously treated with immune checkpoint inhibitors in Korea [JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. |
SCIE | 1.7 |
ONCOLOGY ONCOLOGY;PHARMACOLOGY & PHARMACY MEDICINE, RESEARCH & EXPERIMENTAL ALLERGY;IMMUNOLOGY CELL BIOLOGY |
phy123@knu.ac.kr; dghong@knu.ac.kr;yschae@knu.ac.kr; majestio@hanmail.net; yschae@knu.ac.kr;hann33@gmail.com; yschae@knu.ac.kr; jjh01@knu.ac.kr; |
||
|
Lee, Sung Sook (Lee, SS) |
Inje Univ, Haeundae Paik Hosp, Inje, South Korea |
|
|
[JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. | SCIE | 1.7 | ONCOLOGY | |||
|
Lee, Yoon Suk (Lee, YS) |
Inje Univ, Ilsan Paik Hosp, Dept Internal Med, Div Gastroenterol,Coll Med, Goyang, South Korea Inje Univ, Ilsan Paik Hosp, Dept Internal Med, Coll Med, Goyang, South Korea Inje Univ, Ilsan Paik Hosp, Coll Med, Dept Internal Med, Goyang, South Korea |
D-1827-2019 LEE, Yoon-Suk |
0000-0002-5835-9417 Lee, Yoon Suk |
[JCR상위 1.7] Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial [JCR상위 35.7] Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study [JCR상위 87.4] Quality Indicators of Endoscopic Retrograde Cholangiopancreatography in Korea [JCR상위 35.7] Quality Indicators of Endoscopic Retrograde Cholangiopancreatography in Korea |
SCIE ESCI |
1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
mdsophie@gmail.com;lhs6865@yuhs.ac; p1052ccy@hanmail.net; |
||
|
Lee, Young Han (Lee, YH) |
Yonsei Univ, Coll Med, Dept Radiol, Seoul, South Korea |
AAJ-8828-2020 AAF-2400-2020 Park, Young-Jae Lee, Jeong Hoon |
0000-0002-5602-391X Lee, Young Han |
[JCR상위 1.7] Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma [JCR상위 7.0] Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial |
SCIE | 1.7 |
ONCOLOGY MULTIDISCIPLINARY SCIENCES |
hyosong77@yuhs.ac; | ||
|
Lencioni, Riccardo (Lencioni, R) |
제1저자 |
Univ Pisa, Sch Med, Dept Diagnost & Intervent Radiol, Pisa, Italy Univ Pisa, Dept Diagnost & Intervent Radiol, Sch Med, Pisa, Italy |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | |
|
Li, Haojia (Li, HJ) |
|
|
[JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study | SCIE | 1.7 | ONCOLOGY | ||||
|
Lim, Myong Cheol (Lim, MC) |
제1저자 | Natl Canc Ctr, Ctr Gynecol Canc, Res Inst & Hosp, Goyang, South Korea |
|
0000-0001-8964-7158 Lim, Myong Cheol |
[JCR상위 1.7] Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS) [JCR상위 9.6] Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial) |
SCIE | 1.7 |
ONCOLOGY OBSTETRICS & GYNECOLOGY;ONCOLOGY |
rohjuwon@hanmail.net; | |
|
Lin, Shi-Ming (Lin, SM) |
Chang Gung Mem Hosp, Linkou Med Ctr, Dept Internal Med, Taoyuan, Taiwan |
NPI-5122-2025 Lin, Shiming |
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Lo, Chingchu (Lo, C) |
St Martin Hosp, Chiayi, Taiwan |
|
|
[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | limys@amc.seoul.kr; | ||
|
Lo, Gin-Ho (Lo, GH) |
E Da Hosp, Kaohsiung, Taiwan |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Lopez Chuken, Yamil Alonso (Chuken, YAL) |
I Can Oncol Ctr, New Leon, Mexico |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. | SCIE | 1.7 | ONCOLOGY | |||
|
Madabhushi, Anant (Madabhushi, A) |
AAG-2908-2019 Madabhushi, Anant |
|
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study |
SCIE | 1.7 | ONCOLOGY | ||||
|
Maghsoudi, Omid Haji (Maghsoudi, OH) |
제1저자 |
|
|
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer | SCIE | 1.7 | ONCOLOGY | |||
|
Mai, Ahn (Mai, A) |
Nhan Dan Gia Dinh Hosp, Gen Surg Dept, Ho Chi Minh City, Vietnam Nhan Dan Gia Dinh Hosp, Dept Gen Surg, Ho Chi Minh City, Vietnam |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Min, Sun Young (Min, SY) |
|
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) | SCIE | 1.7 | ONCOLOGY |
페이지 이동: